XML 53 R31.htm IDEA: XBRL DOCUMENT v3.22.4
Revenue (Tables)
 12 Months Ended
Dec. 31, 2022
Grants, U.S. Government Contract and Joint Venture [Abstract]  
Schedule of Accounts Receivable, Unbilled Services, and Deferred Revenue During the years ended December 31, 2022 and 2021, changes in the Company's accounts receivables, deferred revenue, and allowance for doubtful accounts balances were as follows (in thousands):
Balance, Beginning of PeriodAdditionsDeductions Balance, End of Period
Accounts receivable:
Year ended December 31, 2022
$454,993 $1,768,457 $(2,127,240)$96,210 
Year ended December 31, 2021
262,012 2,432,268 (2,239,287)454,993 
Allowance for doubtful accounts:
Year ended December 31, 2022
— 
(13,835)(1)
— (13,835)
Year ended December 31, 2021
— — — — 
Deferred revenue(2):
Year ended December 31, 2022
1,595,472 46,908 
(1,092,829)(3)
549,551 
Year ended December 31, 2021
273,228 1,598,152 (275,908)1,595,472 
(1)    Bad debt expense was $13.8 million in the year ended December 31, 2022 and there was no bad debt expense in the years ended December 31, 2021 and 2020.
(2)    Amount is comprised of $0.4 billion, $1.4 billion, and $0.3 billion current Deferred revenue and $179.4 million, $172.5 million, and no non-current Deferred revenue as of December 31, 2022, 2021, and 2020 respectively.
(3)    Deductions from Deferred revenue include the following: $273.8 million that was realized in Revenue and $819.0 million, including $697.4 million related to the Advance Payment Amount (as described below) at issue in the Gavi arbitration and $112.5 million related to the Amended and Restated UK Supply Agreement, that was reclassified to Other current liabilities, as described below. In the fourth quarter of 2022, the Company recognized revenue of $41.9 million related to a change in estimate attributed to changes in constraint of variable consideration.
Schedule of Product Revenue
Product revenue by the Company’s customer’s geographic location was as follows (in thousands):
Year Ended
December 31, 2022
North America
$194,480 
Europe823,542 
Rest of the world
536,939 
Total product revenue$1,554,961 
Schedule of Grant Revenue
The Company recognized grant revenue as follows (in thousands):
Year Ended December 31,
202220212020
USG Agreement
$380,996 $788,953 $204,727 
U.S. DoD
1,925 21,683 12,519 
CEPI
— 135,445 223,158 
Other grant revenue
— 2,628 12,806 
Total grant revenue$382,921 $948,709 $453,210